After a pause in key grant-review meetings by the NIH, the process is gradually resuming, signaling a potential restoration of funding for biomedical research. This year, the NIH has awarded about $2.8 billion less than average in prior years, raising concerns among scientists about the impact on clinical research. The president's decision to halt these meetings prompted fears of disrupted funding for critical studies. However, recent developments indicate a renewed focus on academic review committees to expedite funding distribution for ongoing and new research projects.
As of 2025, the NIH has awarded about $2.8 billion less than usual at this point over the past five years, indicating a restoration of funding flow.
The NIH's funding pause disrupted ongoing, time-sensitive research, alarming scientists who feared for the future of critical clinical trials.
Collection
[
|
...
]